Quarterly ResultMay 8, 2026, 06:52 AM
ANI Pharmaceuticals Q1 Revenue +20.5% to $237.5M; Raises 2026 Guidance
AI Summary
ANI Pharmaceuticals reported strong first-quarter 2026 financial results, with net revenues increasing 20.5% year-over-year to $237.5 million and adjusted non-GAAP EBITDA rising 24.1% to $63.0 million. The company also raised its full-year 2026 financial guidance for total net revenue, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS, reflecting confidence in continued growth. Additionally, the Board of Directors authorized a new $100 million share repurchase program.
Key Highlights
- Q1 2026 net revenues increased 20.5% year-over-year to $237.5 million.
- Purified Cortrophin® Gel net revenues grew 42.1% to $75.1 million in Q1 2026.
- Adjusted non-GAAP EBITDA rose 24.1% to $63.0 million for the first quarter.
- Diluted GAAP income per share was $1.28, and adjusted non-GAAP diluted EPS was $2.05.
- Raised 2026 total net revenue guidance to $1,080 million - $1,140 million.
- Raised 2026 adjusted non-GAAP EBITDA guidance to $285 million - $300 million.
- Board authorized a new $100 million share repurchase program through May 2029.
- Generics net revenues increased 6.8% to $105.4 million in Q1 2026.